key: cord-0911428-odljg5fp
authors: Demoulin, Nathalie; Scohy, Anaïs; Gillion, Valentine; Godefroid, Nathalie; Jadoul, Michel; Morelle, Johann
title: Low rates of humoural response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab
date: 2021-06-11
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab102
sha: 4540f8b7ae96faedd4a7c7e396759579016628a1
doc_id: 911428
cord_uid: odljg5fp

nan

Patients receiving rituximab are at high risk for life-threatening coronavirus disease 2019 (COVID-19), stressing the need for effective prevention strategies [1] . A two-dose regimen of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech) confers 95% protection against COVID-19 and elicits a humoural response in 95.5% of the general population [2, 3] . Because rituximab depletes B cells and impairs response to influenza vaccination [4, 5] , it is expected to alter immunization after COVID-19 vaccines.

Here we investigated for the first time the humoural response after two doses of BNT162b2 in patients with immune-mediated kidney disease treated with rituximab. Eleven consecutive patients were included ( Table 1 ). The median age was 38 years [interquartile range (IQR) 36-61] and the last rituximab dose was administered 2.4 months (IQR 1.9-4.9) before the first vaccine dose. All patients were in disease remission under rituximab monotherapy.

Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) were measured using an electrochemiluminescent immunoassay (Roche Diagnostics, Basel, Switzerland) at baseline and 28 days after the second vaccine dose. Two patients had detectable baseline anti-RBD antibodies; after vaccination they maintained or increased their antibody levels. Of the nine remaining patients, only three (33%) mounted a serological response following vaccination. Two of them (66%) had detectable CD19 þ B cells versus only one among the six (17%) non-responders. One patient (no. 6) developed a flare of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 2 days after the second vaccine dose and required steroids and cyclophosphamide on top of rituximab.

These data demonstrate a poor humoural response to BNT162b2 vaccination in patients with immune-mediated kidney disease receiving rituximab. Postponing vaccination !6 months after the last rituximab dose and/or after repopulation of CD19 þ lymphocytes may be considered to improve the immunization rate.

The data underlying this article are available upon reasonable request to the corresponding author. 

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients

The results presented in this article have not been published previously in whole or part. The authors have no conflicts of interest relevant to this article.